Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer’s drug success
admin Next stop regulatory approval. That was the view of analysts at Mizuho Securities, who late…
Read Moreproducts
Eisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
Eisai Co. shares were indicated sharply higher Wednesday morning after the Japanese drug maker and…
Read MoreApple won’t boost production of iPhone 14 due to slower demand: report
Apple Inc. is dropping plans to boost production of its latest iPhones this year after…
Read MoreApple won’t boost production of iPhone 14 due to slower demand: report
Apple Inc. is dropping plans to boost production of its latest iPhones this year after…
Read MoreAlzheimer’s drug from Eisai, Biogen shows promise in large trial
Eisai Co. 4523, +0.89% and Biogen Inc. BIIB, +1.04% said their experimental Alzheimer’s disease drug…
Read MoreMoore’s Law ‘alive and well’ as Intel CEO pushes back at Nvidia, launches budget gaming card
Intel Corp. disagrees with Nvidia Corp. when it comes to Moore’s Law as Intel Chief…
Read MoreRobinhood releases crypto wallet with Polygon for select users
Trading app Robinhood Markets Inc. has finally rolled out a noncustodial crypto wallet to 10,000…
Read MoreWill all cars have alcohol detectors in the next few years?
The federal government could require new cars to have anti-drunk-driving systems within three years. A…
Read MoreIf chip production is recovering, why are automakers still making fewer cars?
Automakers trimmed 76,000 vehicles from global production plans in mid-September, according to analysts from AutoForecast…
Read More
‘If the FDA is expected to do more, it needs more’: FDA investigation into baby-formula crisis points to its own shortcomings. But shortages persist.
The Food and Drug Administration spent months probing the nationwide shortage in baby formula, and…
Read More